Results 171 to 180 of about 1,552,889 (274)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Carbon emission analysis and evaluation of steel-concrete composite structure bridge based on fuzzy comprehensive evaluation comprehensive evaluation method. [PDF]

Sci Prog
Li Y, Qiao W, Yang F, Zhou T, Quan H.
europepmc   +1 more source

Study on Forming Law and Penetration of a Spherical Cone Composite Structure Liner Based on the Explosion Pressure-Coupling Constraint Principle. [PDF]

Materials (Basel), 2022
Han J, Du Z, Zheng C, Wang Y, Shang Y, Huang W, Wang X, Zhao J.   +7 more
europepmc   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

High-Energy Low-Velocity Impact Behavior of Rubber-Coated Sandwich Composite Structure with Buoyancy Material Core: Experimental and Numerical Investigation. [PDF]

Materials (Basel)
Zhu Y, Mei Z, Li H, Tao H, Chen G.
europepmc   +1 more source

Synthesis and Characterization of Sn/SnO₂/C Nano-Composite Structure: High-Performance Negative Electrode for Lithium-Ion Batteries. [PDF]

Materials (Basel), 2022
Saddique J, Shen H, Ge J, Huo X, Rahman N, Mushtaq M, Althubeiti K, Al-Shehri H.   +7 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Facile Synthesis of MoP and Its Composite Structure with Ru as an Efficient Electrocatalyst for Hydrogen Evolution Reaction in Both Acidic and Alkaline Conditions. [PDF]

Materials (Basel)
Ren P, Wang R, Yang Y, Wang T, Hong Y, Zheng Y, Zheng Q, Ren X, Jia Z.   +8 more
europepmc   +1 more source

Polymer Foam Concrete FC500 Material Behavior and Its Interaction in a Composite Structure with Standard Cement Concrete Using Small Scale Tests. [PDF]

Polymers (Basel), 2022
Papán D, Ďugel D, Papánová Z, Ščotka M.   +3 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source